What is the appropriate management approach for refractory eczema?

Management of Refractory Eczema

For refractory atopic dermatitis in adults, dupilumab, tralokinumab, abrocitinib, baricitinib, or upadacitinib are strongly recommended as first-line systemic therapies, with dupilumab being the preferred initial choice given its strong safety profile and efficacy. 1, 2

Initial Verification Steps

Before escalating to systemic therapy, confirm true refractoriness by ensuring:

• Adequate trial of intensive topical therapy: Medium- to high-potency topical corticosteroids (TCS) once or twice daily for 1-4 weeks, followed by proactive maintenance therapy with TCS or tacrolimus 2-3 times weekly 3
• Exclusion of secondary infections: Identify and treat bacterial (Staphylococcus aureus) or viral superinfections before systemic therapy 3
• Rule out alternative diagnoses: Consider cutaneous T-cell lymphoma, contact dermatitis, psoriasis, or scabies in atypical presentations 3
• Address adherence barriers: Complex regimens or steroid phobia may falsely suggest refractoriness 3

Systemic Treatment Algorithm

First-Line Systemic Agents (Strong Recommendations)

The 2024 AAD guidelines provide strong recommendations for five agents 1:

1. Dupilumab (IL-4/IL-13 inhibitor)

   • 42% reduction in severity scores 3
   • Safest long-term profile with no required monitoring 3
   • Main side effects: injection site reactions, conjunctivitis 3
   • Preferred initial systemic choice 2

2. JAK Inhibitors (abrocitinib, baricitinib, upadacitinib)

   • Reserved for severe/refractory cases with dupilumab intolerance 2
   • Carry significant risks requiring careful patient selection 2

3. Tralokinumab (IL-13 inhibitor)

   • Alternative biologic option with strong recommendation 1

Second-Line Options (Conditional Recommendations)

The following receive conditional recommendations in favor 1:

• Phototherapy: Useful adjunct without systemic exposure
• Cyclosporine: 73% reduction in severity scores, but requires monitoring of renal function, blood pressure, CBC, lipids 3
• Azathioprine: 26-39% efficacy, requires thiopurine methyltransferase testing, CBC, and liver function monitoring 3
• Methotrexate: Limited efficacy data, requires hepatotoxicity and hematologic monitoring 3
• Mycophenolate: Conditional recommendation with monitoring requirements 1

Agents NOT Recommended

Systemic corticosteroids receive a conditional recommendation AGAINST use 1, 2 due to rebound flares and long-term adverse effects.

Pediatric Considerations

For children with refractory disease 4:

• Dupilumab remains strongly recommended 2
• Wet-wrap therapy and bleach baths may provide benefit in selected cases 4, 2
• Antihistamines are no longer routinely recommended 4
• Elimination diets are not recommended 2

Critical Decision Points

When dupilumab fails or is not tolerated: Consider oral JAK inhibitors despite their risks, as they represent the next tier of evidence-based therapy 2. Weigh cardiovascular, thrombotic, and malignancy risks against disease burden.

When cost/access limits biologic use: Cyclosporine offers the highest efficacy (73%) among traditional immunosuppressants but requires intensive monitoring 3. Limit duration to avoid nephrotoxicity.

Common Pitfalls

• Premature escalation: Ensure 1-4 weeks of intensive topical therapy before declaring refractoriness 3
• Missing infection: Bacterial/viral superinfection mimics treatment failure 3
• Steroid phobia: Address patient concerns about TCS safety to improve adherence 4
• Inadequate moisturization: Consistent emollient use is foundational and prevents flares 4

The evidence strongly favors biologics (particularly dupilumab) and JAK inhibitors over traditional immunosuppressants for refractory disease, representing a paradigm shift from the 2017 guidelines 3 to current 2024 recommendations 1.